Dec. 27th, 2014
Mayo Clinic customers can now order both AFP-L3 and DCP using a single Test ID (Order Code).
AFP-L3 and DCP are biomarkers with regulatory clearance for the use in risk assessment of hepatocellular carcinoma (HCC). Research and clinical findings have shown that the use of the two biomarkers in combination can improve the ability to find HCC at an early stage. As such the two biomarkers are regularly ordered together.
Mayo Medical Laboratories created a new Test ID called HCC Risk Panel which consists of the two biomarkers to ease the ordering process. The panel can be ordered using the Test ID, HCCPR.
Other reference laboratories similarly offer the panel as a single test code. Please contact your preferred reference laboratory to obtain their HCC risk assessment panel code. Please note that panel names vary from laboratory to laboratory.
Clinical Diagnostic and
HCC Biomarkers and
Wako is a comprehensive manufacturer of Clinical Diagnostic reagents that are of the highest quality and good value to performance. Our products are the result of nearly 90 years of dedication to the field of in vitro diagnostics.
For Hepatocellular Carcinoma (HCC) Risk Assessment
Adding the two biomarkers, AFP-L3 and DCP, to your current HCC surveillance practice can increase your chances of detecting early HCC. These tests are available now through major reference laboratories in the United States and Canada.
Wako is a leading manufacturer of the highest quality chemistry reagents worldwide. Our products are the result of over 90 years of dedication to the field of laboratory science and research development. Our superior research reagents are easy to use and have a robust history of utilization in academia.